JP2018536697A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536697A5
JP2018536697A5 JP2018534025A JP2018534025A JP2018536697A5 JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5 JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
composition according
protein
homeoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018534025A
Other languages
English (en)
Japanese (ja)
Other versions
JP6860575B2 (ja
JP2018536697A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/072675 external-priority patent/WO2017071889A1/en
Publication of JP2018536697A publication Critical patent/JP2018536697A/ja
Publication of JP2018536697A5 publication Critical patent/JP2018536697A5/ja
Application granted granted Critical
Publication of JP6860575B2 publication Critical patent/JP6860575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018534025A 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質 Active JP6860575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306482.9 2015-09-23
EP15306482 2015-09-23
PCT/EP2016/072675 WO2017071889A1 (en) 2015-09-23 2016-09-23 Homeoproteins for use in the treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
JP2018536697A JP2018536697A (ja) 2018-12-13
JP2018536697A5 true JP2018536697A5 (enExample) 2019-09-05
JP6860575B2 JP6860575B2 (ja) 2021-04-14

Family

ID=54207439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534025A Active JP6860575B2 (ja) 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質

Country Status (7)

Country Link
US (2) US20190247461A1 (enExample)
EP (2) EP3960195B1 (enExample)
JP (1) JP6860575B2 (enExample)
CN (1) CN108289929A (enExample)
ES (2) ES3010130T3 (enExample)
PL (2) PL3352777T3 (enExample)
WO (1) WO2017071889A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026503094A (ja) 2023-01-13 2026-01-27 ブレインエバー 安定化エングレイルドタンパク質水性組成物
EP4781999A1 (en) * 2025-01-24 2026-07-29 Brainever Engrailed protein for use in the treatment of tdp-43 proteinopathies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
FR2926023B1 (fr) 2008-01-09 2010-02-26 Centre Nat Rech Scient Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
JP2012532621A (ja) * 2009-07-13 2012-12-20 ザ ユニバーシティ オブ サリー 治療ペプチド、ポリペプチド及び核酸配列
WO2013128239A1 (en) 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Similar Documents

Publication Publication Date Title
JP2019524822A5 (enExample)
WO2017070647A8 (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
HRP20191055T1 (hr) Terapeutska sredstva za neurodegenerativne bolesti
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
EP3405215A4 (en) METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
JP2016535786A5 (enExample)
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
EA201991756A1 (ru) Бисгетероарильные производные в качестве модуляторов агрегации белков
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2017062500A3 (en) Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
EA201991374A1 (ru) Водорастворимое производное эпиаллопрегнанолона и его применение
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
IL278813A (en) Gene therapy for Alzheimer's disease
JP2016523969A5 (enExample)
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
EP3639839A4 (en) PEPTIDE WITH ANTIDEPRESSIVE EFFECT AND THERAPEUTIC EFFECT AGAINST ALZHEIMER'S MORBUS
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
WO2019070727A3 (en) Nonviral gene transfer to the suprachoroidal space
EA201991753A1 (ru) Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
SI3413870T1 (sl) Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni
WO2017079161A3 (en) Treatment of neurodegenerative disease with sodium chlorite